XTL Begins Phase IIb Clinical Trial
XTL Biopharmaceuticals Ltd. (XTLB) began a Phase IIb clinical trial of its diabetic neuropathic pain treatment Bicifadine. The stock price surged 39 cents to close at $1.74.
posted by FC Market News at 10:20 AM
0 Comments:
Post a Comment
<< Home